Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis.
Greer YE, Hernandez L, Fennell EMJ, Kundu M, Voeller D, Chari R, Gilbert SF, Gilbert TSK, Ratnayake S, Tang B, Hafner M, Chen Q, Meerzaman D, Iwanowicz E, Annunziata CM, Graves LM, Lipkowitz S. Greer YE, et al. Among authors: fennell emj. Cancer Res Commun. 2022 Oct 10;2(10):1144-1161. doi: 10.1158/2767-9764.CRC-22-0142. Cancer Res Commun. 2022. PMID: 36388465 Free PMC article.
Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.
Graves PR, Aponte-Collazo LJ, Fennell EMJ, Graves AC, Hale AE, Dicheva N, Herring LE, Gilbert TSK, East MP, McDonald IM, Lockett MR, Ashamalla H, Moorman NJ, Karanewsky DS, Iwanowicz EJ, Holmuhamedov E, Graves LM. Graves PR, et al. Among authors: fennell emj. ACS Chem Biol. 2019 May 17;14(5):1020-1029. doi: 10.1021/acschembio.9b00222. Epub 2019 May 1. ACS Chem Biol. 2019. PMID: 31021596 Free PMC article.
Correction to "Mitochondrial Protease ClpP Is a Target for the Anticancer Compounds ONC201 and Related Analogues".
Graves PR, Aponte-Collazo LJ, Fennell EMJ, Graves AC, Hale AE, Dicheva N, Herring LE, Gilbert TSK, East MP, McDonald IM, Lockett MR, Ashamalla H, Moorman NJ, Karanewsky DS, Iwanowicz EJ, Holmuhamedov E, Graves LM. Graves PR, et al. Among authors: fennell emj. ACS Chem Biol. 2022 Aug 19;17(8):2377-2378. doi: 10.1021/acschembio.2c00545. Epub 2022 Jul 25. ACS Chem Biol. 2022. PMID: 35878877 Free PMC article. No abstract available.
Characterization of TR-107, a novel chemical activator of the human mitochondrial protease ClpP.
Fennell EMJ, Aponte-Collazo LJ, Wynn JD, Drizyte-Miller K, Leung E, Greer YE, Graves PR, Iwanowicz AA, Ashamalla H, Holmuhamedov E, Lang H, Karanewsky DS, Der CJ, Houry WA, Lipkowitz S, Iwanowicz EJ, Graves LM. Fennell EMJ, et al. Pharmacol Res Perspect. 2022 Aug;10(4):e00993. doi: 10.1002/prp2.993. Pharmacol Res Perspect. 2022. PMID: 35929764 Free PMC article.
Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer.
Fennell EMJ, Aponte-Collazo LJ, Pathmasiri W, Rushing BR, Barker NK, Partridge MC, Li YY, White CA, Greer YE, Herring LE, Lipkowitz S, Sumner SCJ, Iwanowicz EJ, Graves LM. Fennell EMJ, et al. Front Pharmacol. 2023 Mar 31;14:1136317. doi: 10.3389/fphar.2023.1136317. eCollection 2023. Front Pharmacol. 2023. PMID: 37063293 Free PMC article.